Literature DB >> 20447651

Response and remission criteria in major depression--a validation of current practice.

Michael Riedel1, Hans-Jürgen Möller, Michael Obermeier, Rebecca Schennach-Wolff, Michael Bauer, Mazda Adli, Klaus Kronmüller, Thomas Nickel, Peter Brieger, Gerd Laux, Wolfram Bender, Isabella Heuser, Joachim Zeiler, Wolfgang Gaebel, Florian Seemüller.   

Abstract

Remission and response were suggested as the most relevant outcome criteria for the treatment of depression. There is still marked uncertainty as to what cut-offs should be used on current depression rating scales. The goal of the present study was to compare the validity of different HAMD, MADRS and BDI cut-offs for response and remission. The naturalistic prospective study was performed in 12 psychiatric hospitals in Germany. All evaluable patients (n=846) were hospitalized and had to meet DSM-IV criteria for major depressive disorder. Biweekly ratings were assessed using HAMD-21, MADRS and BDI. A CGI-S score of 1 and a CGI-I score of at least 2 was used as the primary comparative measure of remission and response, respectively. A HAMD-21 cut-off ≤7 (AUC: 0.92), HAMD-17 cut-of ≤6 (AUC: 0.90), MADRS cut-off ≤7 (AUC: 0.94) and BDI cut-off ≤12 (AUC: 0.83) were associated with a maximum of specificity and sensitivity for defining remission. A minimum decrease of 47% of the HAMD-21 (AUC: 0.90), ≤57% for HAMD-17 (AUC: 0.89), ≤ 46% for MADRS (0.91) and a decrease of 47% for the BDI baseline score (AUC: 0.78) best corresponded CGI response criteria. Our data largely confirmed currently used remission and response criteria in naturalistically treated patients.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20447651     DOI: 10.1016/j.jpsychires.2010.03.006

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  80 in total

1.  Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder.

Authors:  Elina A Stefanovics; Robert A Rosenheck; Karen M Jones; Grant Huang; John H Krystal
Journal:  Psychiatr Q       Date:  2018-03

2.  Neuropsychological deficits in past suicide attempters with varying levels of depression severity.

Authors:  J G Keilp; S R Beers; A K Burke; N M Melhem; M A Oquendo; D A Brent; J J Mann
Journal:  Psychol Med       Date:  2014-04-09       Impact factor: 7.723

3.  A Randomized Controlled Trial: Attachment-Based Family and Nondirective Supportive Treatments for Youth Who Are Suicidal.

Authors:  Guy S Diamond; R Roger Kobak; E Stephanie Krauthamer Ewing; Suzanne A Levy; Joanna L Herres; Jody M Russon; Robert J Gallop
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2018-10-30       Impact factor: 8.829

4.  Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.

Authors:  Florian Seemüller; Sebastian Meier; Michael Obermeier; Richard Musil; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Michael Riedel; Peter Falkai; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-03-04       Impact factor: 5.270

Review 5.  The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder.

Authors:  Anthony L Vaccarino; Kenneth R Evans; Amir H Kalali; Sidney H Kennedy; Nina Engelhardt; Benicio N Frey; John H Greist; Kenneth A Kobak; Raymond W Lam; Glenda MacQueen; Roumen Milev; Franca M Placenza; Arun V Ravindran; David V Sheehan; Terrence Sills; Janet B W Williams
Journal:  Innov Clin Neurosci       Date:  2016-10-01

6.  Preliminary long-term follow-up of Mindfulness-based cognitive therapy-induced remission of depression.

Authors:  Krishna Munshi; Stuart Eisendrath; Kevin Delucchi
Journal:  Mindfulness (N Y)       Date:  2013-12-01

7.  Remission prognosis for cognitive therapy for recurrent depression using the pupil: utility and neural correlates.

Authors:  Greg J Siegle; Stuart R Steinhauer; Edward S Friedman; Wesley S Thompson; Michael E Thase
Journal:  Biol Psychiatry       Date:  2011-04-15       Impact factor: 13.382

8.  Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder.

Authors:  Alberto Chiesa; Concetta Crisafulli; Stefano Porcelli; Changsu Han; Ashwin A Patkar; Soo-Jung Lee; Moon Ho Park; Tae-Youn Jun; Alessandro Serretti; Chi-Un Pae
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-05       Impact factor: 5.270

9.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

10.  Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.

Authors:  Chi-Un Pae; Prakash S Masand; Francine S Mandel; Cedric O'Gorman
Journal:  Clin Drug Investig       Date:  2012-11       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.